A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)

Gynecologic Oncology
H HirteLesley Seymour

Abstract

Approximately 50% of ovarian cancers have elevated levels of epidermal growth factor receptor (EGFR) which correlates with a poor prognosis. Preclinical evidence suggests that EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib (OSI-774), may potentiate the anti-tumour effects of cytotoxic agents, including carboplatin. Blocking EGFR could thus potentially reverse drug resistance. The primary objective of the study was to assess the response rate to the addition of erlotinib in patients with recurrent ovarian cancer who were receiving carboplatin. Patients enrolled on this study had either local or advanced recurrent ovarian cancer with measurable disease. They may have had up to 2 prior chemotherapy regimens, one of which must have contained platinum, and they must have responded to prior platinum therapy. Patients were stratified by platinum sensitivity and were treated with erlotinib 150 mg daily on a continuous dosing schedule, and carboplatin at an AUC of 5 every 21 days. Fifty patients with recurrent ovarian cancer entered the study, 33 in the platinum-sensitive arm and 17 in the platinum-resistant arm. Of patients evaluable for response, there were 14 partial responses (PR) of 30 evaluable for response (57% objecti...Continue Reading

References

Jan 1, 1992·Urologia Internationalis·D E Neal, K Mellon
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B J FosterA H Calvert
Jul 1, 1995·Critical Reviews in Oncology/hematology·D S SalomonN Normanno
Jul 21, 1993·Journal of the National Cancer Institute·M D BrundageB Zee
Oct 1, 1996·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·J B Vermorken, S Pecorelli
Aug 1, 1997·Gynecologic Oncology·J V IlekisB Scoccia
Aug 24, 1999·Pharmacology & Therapeutics·J R Woodburn
Sep 20, 2001·Journal of the National Cancer Institute· Alper OW G Stetler-Stevenson
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susana CamposHal Hirte
Sep 10, 2005·International Journal of Cancer. Journal International Du Cancer·Ludovic LacroixJean-Charles Soria
Sep 22, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A N GordonE Barrett
Mar 24, 2006·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Sylvia StadlmannGad Singer
Apr 12, 2006·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Heini LassusRalf Butzow
Aug 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael S GordonBeth Y Karlan
Mar 19, 2008·Molecular Cancer Therapeutics·Valentina BenedettiFranco Zunino
Jun 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karina Dahl SteffensenAnders Jakobsen
Aug 14, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Callum M SlossJames C Cusack
Sep 23, 2008·International Journal of Cancer. Journal International Du Cancer·Tiziana ServideiRiccardo Riccardi
Nov 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sharmila MakhijaUrsula Matulonis

❮ Previous
Next ❯

Citations

Oct 4, 2012·Future Oncology·Klaus H BaumannAndreas du Bois
Jan 10, 2014·Molecular Diagnosis & Therapy·Henry D ReyesKimberly K Leslie
Jan 12, 2012·Journal of Oncology·Tomoko TagawaJoanne Mortimer
Jul 5, 2012·Women's Health·Ashley Stuckey, Don S Dizon
Jul 8, 2011·Cancer Management and Research·Gina M Mantia-SmaldoneAnda M Vlad
Apr 19, 2013·Journal of Cancer Research and Clinical Oncology·Linjuan XuZehua Wang
Nov 13, 2015·Expert Opinion on Investigational Drugs·Zhijie Wang, Siqing Fu
Jul 3, 2013·Expert Opinion on Investigational Drugs·Matteo MorottiSimone Ferrero
Mar 26, 2011·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Mark Murphy, Britta Stordal
Apr 9, 2016·Gynecologic Oncology·M PetrilloG Scambia
Apr 9, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Robert L ColemanMaurie Markman
Sep 13, 2014·Cancer Chemotherapy and Pharmacology·Alvaro Henrique Ingles GarcesAndréia Cristina de Melo
Aug 4, 2016·Cancer Investigation·Ioannis Ntanasis-StathopoulosElias A Kotteas
Nov 10, 2016·Expert Review of Molecular Diagnostics·Rebecca A PrevisShannon N Westin
Apr 27, 2017·Critical Reviews in Clinical Laboratory Sciences·Khalid El BairiSaid Afqir
Oct 7, 2011·The Cochrane Database of Systematic Reviews·Krishnayan HaldarJo Morrison
Oct 16, 2018·The Cochrane Database of Systematic Reviews·Jo MorrisonAndrew Bryant
Jun 15, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Don S DizonRichard T Penson
Mar 6, 2010·Cancer Chemotherapy and Pharmacology·Martin PölcherChristian Rudlowski
Mar 16, 2012·Future Medicinal Chemistry·Jason A WilkenNita J Maihle
Sep 25, 2019·Cancers·Periklis KatopodisEmmanouil Karteris
Dec 23, 2016·Oncotarget·Kevin BrasseurEric Asselin
May 6, 2020·International Journal of Molecular Sciences·Maria KrchniakovaRenata Veselska
Jul 31, 2020·Signal Transduction and Targeted Therapy·Qiao WangXia Zhao
Oct 17, 2013·Molecular Cancer Therapeutics·Marc A BeckerPaul Haluska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.